Skip to main content

Table 3 Cytokines and coagulation parameters in 74 COVID-19 patients stratified according to high (≥ median) versus low (< median) IP-10

From: IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19

 

Total (N = 74)

IP-10

P

Low (N = 34)

High (N = 40)

n

Median (IQR)

n

Median (IQR)

n

Median (IQR)

IL-1β, pg/mL

29

5.0 (5.0–5.0)

11

5.0 (5.0–5.0)

18

5.0 (5.0–7.3)

0.253

IL-2R, U/mL

30

1055.5 (464.5–1609.5)

12

784.0 (362.8–1256.3)

18

1311.5 (721.0–1957.0)

0.099

IL-6, pg/mL

48

74.2 (17.0–157.5)

23

26.3 (9.6–95.9)

25

114.8 (54.6–343.1)

0.001

IL-8, pg/mL

29

51.7 (12.5–114.7)

11

19.5 (10.1–51.7)

18

78.8 (22.3–156.0)

0.018

IL-10, pg/mL

29

11.4 (5.0–20.1)

11

5.0 (5.0–9.0)

18

16.8 (8.5–36.4)

0.001

TNFα, pg/mL

27

12.7 (7.5–28.7)

10

8.6 (5.5–10.7)

17

16.2 (8.9–37.1)

0.021

Prothrombin time (PT), s

71

15.9 (14.9–18.2)

32

15.6 (14.7–17.3)

39

16.9 (15.3–19.0)

0.029

Prothrombin activity (PTA), %

71

69.0 (55.0–80.0)

32

71.5 (60.0–80.8)

39

63.0 (51.0–74.0)

0.025

International normalized ratio (INR)

71

1.26 (1.15–1.49)

32

1.24 (1.14–1.41)

39

1.36 (1.20–1.58)

0.026

Fibrinogen (FIB), g/L

71

4.2 (3.1–5.2)

32

4.0 (3.5–4.7)

39

4.6 (2.5–5.7)

0.675

Activated partial thromboplastin time (APTT), s

71

44.5 (39.3–52.6)

32

43.0 (37.5–50.2)

39

46.8 (40.7–57.4)

0.069

Thrombin time (TT), s

71

15.3 (14.5–16.5)

32

15.1 (14.4–15.8)

39

15.8 (14.9–17.7)

0.016

d-Dimer, μg/mL FEU

71

3.85 (1.68–13.46)

32

2.52 (1.32–8.56)

39

5.73 (2.33–18.00)

0.056

Fibrin degradation products (FDP), μg/mL

30

17.2 (6.2–68.6)

13

9.4 (4.0–52.3)

17

17.7 (13.6–130.5)

0.089

Antithrombin (AT), %

34

80.5 (65.5–88.5)

16

83.0 (66.8–92.3)

18

78.5 (62.5–85.8)

0.48

  1. Bold indicates the statistically significant values (P < 0.05)